Sir,
Small bowel adenocarcinoma (SBA) is a rare and aggressive tumour. SBA in the United States increased from 5.7 cases per million in 1973 to 7.3 cases per million in 2004 (Surveillance Epidemiology and End Results (SEER), 1973–2004 database; Jemal et al (2009). Surgery is the mainstay of treatment, even if chemotherapy in advanced disease has been associated with an increased survival. The most effective agents include 5-FU, irinotecan, platinum agents and gemcitabine (Fishman et al, 2006; Speranza et al, 2010). The molecular characterisation of this cancer could help to improve prognosis. Specifically, the frequency of KRAS gene mutations is similar than in colorectal cancer (Ari et al, 1997). The role of targeted therapy, specifically of epidermal growth factor receptor (EGFR) inhibitors, has never been investigated in patients with SBA. A recent report showed that a high percentage of tumours express both EGFR and VEGF-A suggesting that these patients could benefit from therapeutic strategies targeting EGFR and VEGF receptors (Overman et al, 2010).
In our institution four patients with advanced SBA (three men and one woman) were enrolled to receive cetuximab in combination with chemotherapy. The primary site of disease was duodenum in two patients and jejunum in the other two patients. All patients had peritoneal carcinosis, whereas one presented also bone, abdominal lymph nodes and liver metastases. Cetuximab (250 mg mq−1, with a loading dose of 400 mg mq−1) was associated with CPT-11-based chemotherapy in first- (two patients) or second-line (two patients) therapy for metastatic disease. The patients previously treated progressed with folfiri during first-line chemotherapy. The median number of weekly cetuximab cycles was 14 (range: 8–28). One patient obtained a complete peritoneal response, two patients a partial peritoneal response and one patient stable disease in all the disease localisations. Two patients have a time to progression with cetuximab of 3 months, whereas the other two are still on cetuximab after 3 and 10 months. Two patients are still alive (overall survival of 7 and 17 months), the other two had an overall survival of 35 and 19 months. Treatment was well tolerated, with one patient presenting grade 3 neutropenia and grade 3 diarrhoea. Nobody needed to have a dose modification. In three patients KRAS status was tested, resulting in KRAS wild-type mutational status. The same patients presented a G2 skin rash, that was associated with the two partial responses and the complete response. Table 1 shows the main characteristics and the results.
These case reports show that anti-EGFR therapy may have a role in SBA, especially in those patients harbouring a wild-type KRAS status. A prospective trial is needed to explore and to support these preliminary observations.
Change history
29 March 2012
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ari M, Shimizu S, Imai Y, Nakatsuru Y, Oda H, Oohara T, Ishikawa T (1997) Mutations of the Ki-ras, p53, and APC genes in adenocarcinomas of the human small intestine. Int J Cancer 70: 512–517
Fishman PN, Pond GR, Moore MJ, Oza A, Burkes RL, Siu LL, Feld R, Gallinger S, Greig P, Knox JJ (2006) Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 29: 225–231
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249
Overman MJ, Pozadzides J, Kopets S, Wen S, Abbruzzese JL, Wolff RA, Wang H (2010) Immunophenotype and molecular characterization of adenocarcinoma of the small intestine. Br J Cancer 102: 144–150
Speranza G, Doroshow JH, Kummar S (2010) Adenocarcinoma of the small bowel: changes in the landscape? Curr Opin Oncol 22: 387–393
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Santini, D., Fratto, M., Spoto, C. et al. Cetuximab in small bowel adenocarcinoma: a new friend?. Br J Cancer 103, 1305 (2010). https://doi.org/10.1038/sj.bjc.6605898
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605898
This article is cited by
-
Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma
Medical Oncology (2020)
-
Management of Advanced Small Bowel Cancer
Current Treatment Options in Oncology (2018)
-
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer
Cancer Chemotherapy and Pharmacology (2017)
-
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma
International Journal of Clinical Oncology (2017)
-
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma
Modern Pathology (2016)